Statin sales were "forced down" 15 new products into the "melee"

Pharmaceutical Network monthly Beijing New Pharmaceuticals announced that the exclusive product pistatin calcium dispersion tablets passed the consistency evaluation to become the seventh rated statinsStatins have been the most popular varieties of blood lipid drugs in the minet net data show that in China's public medical institutions terminal blood lipid regulator varieties have a statin (including compound preparations) in the national collection of the first round (in the League region) in the list of atovastatin calcium tablets, resuvastatin calcium tablets in the second round has simetalatin tablets third round has been in the string of his oral regular releaseDespite his much-loved statins, what "new blood" potential exists in the market for now-hot market-to-life lipid regulators? Sub-category ranking rose to the top ten products statins baritone chart: China's public medical institutions terminal lipid regulator market situation source: Minet China public medical institutions terminal competitive pattern of hyperlipidemia is a common disease in the elderly as an important subcategory of cardiovascular system drugs its clinical demand is also increasing year by yearMinet data show that the annual share of end-of-life lipid regulators in the cardiovascular system drug market in Chinese cities, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) has also increased year by yearThe annual ranking of lipid regulators rose but the sales growth rate showed the first decline in the overall sales scale of about 100 million yuanTable: Annual blood lipid regulator product situation (units: billion yuan) Source: Minet China public medical institutions terminal competition pattern from product sales situation, products for his statins (including compound preparations) which atorvastatin calcium tablets, resuvastatin calcium tablets, atorvastatin calcium capsules and pivastatin calcium tablets for the super billion productsThe first round of national collection (pilot city, alliance area) Atavastatin calcium tablets, reshvastatin calcium tablets became the representative of blood lipid regulators: the pilot city collection by the Jialin Pharmaceuticals, Beijing New Pharmaceuticals exclusive winning bid unit price for metatablets (), meta tablets (); When the collection of Atavastatin calcium tablets by Qilu Pharmaceuticals, Xing'an Pharmaceuticals, Lepu Pharmaceuticals share market price for meta tablets (), meta-chips (), meta-chips () and meta-tablets () Rysuvastatin calcium tablets by Hanyu Pharmaceuticals, Sanders, Nanjing Zhengda Tianqing share market winning price is yuan (), yuan (), yuan ()Participating in the collection of enterprises more and more visible large varieties of the market more and more fierce competition, especially for some clinically very mature varieties to win the collection of the entrance ticket equal to win the hospital terminal in exchange for the amount of some "barefoot" enterprisesHowever, for the two large varieties of Atovastatin calcium tablets, rishuavastatin calcium tablets, due to the original high demand for such floor prices also have a serious impact on the overall sales scaleThe sales growth rate of these two megabillionias in China's public medical facilities terminals was negative for the first time in four yearsFrom the situation of the winning enterprise, the current final situation of the exclusive winning bid enterprise Jialin, the exclusive winning bid enterprise in the pilot city of Atorvastatin, is still waiting for the market results in the fourth quarter of the year to the first quarter of the yearBut there is no doubt that the collection for Qilu Pharmaceuticals, Xing'an Pharmaceuticals, such as "light foot" enterprises are certainly goodRuishuvastatin calcium tablet pilot city exclusive winning bid enterprise Jingxin Pharmaceutical annual sales growth rate of the alliance area winning the Hanyu Pharmaceutical, Sanders, Nanjing Zhengda Tianqing are supplementary applications approved low-cost winning bid is undoubtedly only to maintain the occupied placeThe second round of national collection has started this year to land Invastatin tablets by Beijing New Pharmaceuticals, Sanders share market winning price is yuan tablets, Yuan film year two enterprises in China's public medical institutions terminal market share, the current market leader Mercadong accounted for more thanIt can be expected that the share of original research under the collection is expected to be further snapped upProduct pistatin calcium tablets are also a billion products a year in multiple statins heavy product sales decline in the situation still maintain the above growth potential can not be underestimatedIt is reported that the third round of national collection has been arrow in the string many places have been carried out the reporting work of pivastatin oral regular release agent form to become the representative of the current round of pivastatin calcium tablets evaluation enterprises have a supplementary application for approval of Jiangsu Wanbang biochemical medicine Group by class imitation approved and regarded as the same as the evaluation of the letter Litai, Nanjing Chango Pharmaceutical Pivastatin calcium dispersed film evaluation enterprises have a supplementary application for approval of Beijing New Pharmaceuticals has the first round of "barefoot" enterprise scarlet experience I believe this round of bidding will also be unusually hot So far a new product approved statin heat table: so far approved blood lipid regulator product sourcing source: Minet China drug review database so far a total of blood lipid regulatorapprove disapproved in addition to Sanofi's AlisiU single anti-injection injection approved imports of other approval s/he approved production (including the same review) are around statin products are expected to predict the future atoftatin, pistatin, risutatin-related products will be more intense market competition Sanofi's inhibitor-type lipid-lowering drug, Alisiusazumab, was approved by the State Drug Administration for listing in adult patients with primary hypercholesterolemia (hybrid familial and non-family) or mixed lipid abnormalities, as well as reducing the risk of cardiovascular events in patients with atherosclerosis cardiovascular disease Currently, two inhibitors approved for listing worldwide are Sanofi Regenerative And Amgen, which was approved in the United States last year as the first approved inhibitor, Amgen (Iloyu sing) Sanofi's application for listing of Alisiyu sing-it injections was included in the priority review on a monthly grant Figure: Has been approved for the Ruishuvastatin calcium dispersion tablets related to the situation source: Minnet net one-click search Zhejiang Jing new drug industry's Ruishuvastatin calcium dispersion tablets for the new specifications approved for listing company in the announcement mentioned that Ruishuvastatin calcium dispersion tablets in the rapid collapse of water especially suitable for the elderly or swallowing difficult patients to improve patient stake compliance Its approval further enriched the company statin series and dosage form is conducive to enhance the company's cardiovascular products market competitiveness Non-statins killed a new drug first imitation will detonate the market table: so far in the review of statins (including compound preparations) product listing application source: Minet China drug review database in the previous years statins in the market such as fish water attracted a lot of enterprises to increase the strength of research and development at the national level of the collection only accept the original research, reference preparations and evaluation products to participate in the original bid for many enterprises that did not enter the market by the new classification of the listing So far statin-related products have a acceptance number declaration listing involving an imported product (a acceptance number) the rest of the acceptance number are generics involving Atovastatin calcium tablets, ammonia chlorate flat atorvastatin calcium tablets, pivastatin calcium tablets, risvastatate calcium tablets, sinvastatin tablets already fierce competition in the market will continue to storm away Table: So far in the review of non-statin products listing application source: Minet China drug review database in everyone is still addicted to enter ingesting on the statin market at the same time a number of domestic research and development strength of pharmaceutical companies have set their sights on other blood lipid regulators on the new products on the market so far a total of non-statin products listed applications in the review (involving a acceptance number) including a class of new drugs domestic first imitation of the competition has also entered the white heat stage Haizheng Pharmaceuticals' Haize Mab tablets were accepted in the annual declaration II III phase clinical trial acceptance of the drug intended for the treatment of primary hypercholesterolemia, The completion of Phase III clinical trial results of the First-phase Heze Mab single drug to achieve a preset standard can reduce the 、、、 level of weekly effectiveness fast and the effect of smooth long-term use of adverse reactions low-safety high tolerance good For patients with high cholesterol haemorrmia who combined atherosclerosis cardiovascular disease and isotropic disease with conventional statin drug treatment that still did not reach the target value, the effect of adding hexemeb to fat reduction was better than statin dose doubling and adverse events and adverse reactions occurred less frequently It is reported that the current foreign has been listed the same action target drug for Mersadon's ethycoma cloth product global sales peak appeared in the annual billion yuan One of the acceptance numbers of the Hezemak film was included in the priority review in the month of the year Mershadon's ethyl-fold wheat cloth tablets are used for primary hypercholesterolemia, pure hematogen family hypercholesterolemia () and pure hematostersteremia (or plant sterolemia) treatment year in China approved the current domestic market there is no generic drugs Ranked ninth in China's public medical institutions in the end-of-the-line lipid regulator products is the only non-statin product on the top 10 The product entered the national health insurance catalog after the rapid growth rate of sales in the year, respectively, is still the version of the National Health Insurance Directory Class B varieties limited use range also from the version of the "limited statin drug treatment effect is not good or non-tolerated patients second-line drug" to "limited statin drug treatment effect is not good or to tolerate patients." At present, domestic pharmaceutical companies have declared a class of imitation from the time point of view of Hunan Fangsheng Pharmaceutical, Beijing Fuyuan Pharmaceutical, Chongqing San Huayu Pharmaceuticals are in the year to host the first imitation of the battle is difficult to distinguish Figure: At present, the domestic market benzene-bettor-related products approved source: Minnet one-click search benzene zabeit is China's public medical institutions terminal blood lipid regulator varieties on the market approved related products including dispersed tablets, capsules and ordinary tablets temporarily without delayed release tablets approved Jiangsu Tianshi Liyi Pharmaceuticals in the month of the year to declare the class of imitation listing was finally approved clinical Shaanxi step high-tech pharmaceutical also declared in the month of the year generic listing in the year was approved for clinical Jiangsu Tianshi Liyi Pharmaceutical signed in the month of the year generic listing is currently in the review and approval in addition to no other enterprises in the acceptance number in the review Omega ethyl acid softgels are mainly used together with low-fat diet to reduce high triglyceride emily disease has not yet entered the Chinese market Abbott trade (Shanghai) declaration class imported domestic pharmaceutical companies in Sichuan State for pharmaceutical, Chengdu Shengdi pharmaceutical declaration class imitation From the time point of view, Hengrui subsidiary Chengdu Shengdi Pharmaceutical in the year to host Sichuan Guo for pharmaceutical in the year to receive the contractor Abbott trade (Shanghai) is the year to get the contractor is ultimately imported first approved or Hengrui took the first imitation we wait to see Source: Minnet database, company announcement review data statistics as of the end of the year, if there is any error leakage please point